Merck Serono, a division of Germany-based Merck, has announced that Erbitux (cetuximab) has demonstrated a significant improvement in overall survival (OS) when added to standard 1st-line chemotherapy for
Plexxikon has reported encouraging clinical data from a phase 1 extension study of PLX4032 (RG7204) in metastatic melanoma patients, which expand the results announced from the initial phase
Zandu Pharmaceutical has announced that the company has received approval from the shareholders for merger with Emami and Emami Infrastructure. Zandu Pharmaceutical had conducted ameeting with the company’s
STELARA (ustekinumab) has been approved by the National Institute for Health and Clinical Excellence (NICE) as a treatment option for adults with moderate to severe plaque psoriasis. STELARA,
Genzyme is now approximately half-way through the anticipated shortage period for Cerezyme and Fabrazyme. The restart of the Allston landing manufacturing facility is complete, and if production continues
Gilead Sciences has revealed that the European Commission has granted conditional marketing authorisation for Cayston 75mg powder and solvent for nebuliser solution for the suppressive therapy of chronic
Pharming Group has received confirmation of validation from EMEA of its Marketing Authorization Application (MAA) for Rhucin. Consequently the formal scientific evaluation procedure of the European Medicines Agency
The US District Court for the Southern District of Indiana has upheld Eli Lilly and company’s method-of-use patents on Evista (raloxifene HCl tablets). In the case of Eli
Edwards Lifesciences has announced that the Court of Appeals for the Federal Circuit affirmed a previous court decision in favor of Cook and WL Gore & Associates. The
GATC Biotech has revealed that it is now offering human genome sequencing services using enrichment technologies from Agilent along with sequencing systems such as Roche GS FLX and
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.